Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Art & Psychiatry
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Conference Oration
Conference Summary
Continuing Medical Education
Cosmetic Dermatology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
Editor Speaks
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Miscellaneous Letter
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News & Views
Observation Letter
Observation Letters
Original Article
Original Contributions
Pattern of Skin Diseases
Pediatric Dermatology
Pediatric Rounds
Presedential Address
Presidential Address
Presidents Remarks
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Review Article
Review Articles
Reviewers 2022
Revision Corner
Self Assessment Programme
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Study Letter
Study Letters
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Review and Meta-Analysis
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapy Letter
Therapy Letters
View Point
What’s new in Dermatology
View/Download PDF

Translate this page into:

Observation Letter

Amivantamab (JNJ-61186372)-induced adverse cutaneous reaction

Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing First People’s Hospital, Chongqing
Department of surgery, RenHuai People’s Hospital, ZunYi, China
Corresponding author: Bing-Jun Shi, Department of Dermatology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing First People’s Hospital, Chongqing, China.
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Cheng J-R, Hui H-Z, Zheng J, Mao H, Wang YJ, Shi B-J. Amivantamab (JNJ-61186372)-induced adverse cutaneous reaction. Indian J Dermatol Venereol Leprol doi: 10.25259/IJDVL_717_2022


The Food and Drug Administration (FDA) granted accelerated approval to amivantamab for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. Activating EGFR mutations render resistance to treatment with EGFR tyrosine kinase inhibitors. This resistance is mediated by multiple mechanisms, which include secondary EGFR mutation and activation of the c-mesenchymal-epithelial transition factor pathway. Amivantamab is a bispecific monoclonal antibody that targets both EGFR and mesenchymal-epithelial transition factor. 1 Acting on both targets provides amivantamab an “avidity effect,” which is superior to poziotinib or cetuximab in terms of therapeutic efficacy. 2 We report a case of adverse cutaneous reaction following amivantamab treatment.

A 53-year-old man without a history of skin disease was diagnosed as right lung adenocarcinoma with multiple mediastinal lymph node metastases. His genetic testing showed epidermal growth factor receptor (EGFR) exon 20 insertion mutations and hence was treated with amivantamab (JNJ61186372)—targeted therapy. The dosage of amivantamab was 1050 mg weekly for the first four weeks, and then every two weeks thereafter. He began to develop facial skin lesions that gradually extended to the scalp, buttocks and lower limbs after three weeks of treatment. He complained of skin pain but without any accompanying constitutional symptoms like fever, breathlessness, facial oedema, jaundice, etc. Dermatological examination showed purulent crusts on the scalp, [Figure 1] scattered erythematous papules on the face, legs and scrotum along with scattered crusts on the face [Figures 24]. Erosive erythema was seen on the perianal area [Figure 5]. Nails showed paronychia-like changes [Figures 6]. The cutaneous adverse events were grade 3 in severity. The pulse, blood, pressure, respiratory rate, temperature, lymph nodes were normal. Scalp pus culture showed S. aureus infection, with sensitivity to amoxicillin, gentamicin and tetracycline. His haemogram, renal and liver function tests, absolute eosinophil count and peripheral smear analysis were within normal limits. He was treated with kangfuxin liquid, compound polymyxin b ointment, compound neomycin ointment and recombinant human epidermal growth factor gel without systemic steroids and continued amivantamab treatment. Skin lesions improved after a week. He received 22 more injections of amivantamab, and the rash appeared basically similar to the initial manifestation after about a week of each infusion. In subsequent recurrences, the pus culture and sensitivity did not reveal any pathogens and each time, the skin lesions responded to recombinant human epidermal growth factor gel, compound polymyxin b ointment and kangfuxin liquid. His scoring was six based on the Naranjo adverse drug reaction probability scale, indicating a probable drug reaction to amivantamab.

Figure 1:: Erosions and purulent crusts on the scalp
Figure 2:: Scattered erythematous papules and crusts on the face.

Amivantamab (30% Relative Risk) is safer and controllable compared with poziotinib, and only mild keratosis appeared on the face in amivantamab-treated BA/F3-bearing NOG mice models.2 Amivantamab has shown no cutaneous adverse effects in trials with cynomolgus monkeys.3 However, during the first infusion, skin lesions were the most common adverse reaction, and nine percent patients had grade 3 severity.4 In the CHRYSALIS phase I study, Park et al. documented adverse events like acneiform eruptions (86%), paronychia (45%), stomatitis (21%), pruritus (17%), diarrhoea (12%), pneumonitis (4%), hypoalbuminemia (27%), peripheral oedema (27%), etc.5 Nonetheless, amivantamab heralds a new era in the treatment of non-small cell lung cancer, but understanding the cutaneous side effects is also important. Kangfuxin liquid is made from American plant extract that is rich in active substances, and in combination with compound polymyxin b ointment and recombinant human epidermal growth factor gel reduces inflammation and promotes epidermal cell growth.6

Figure 3:: Scattered erythematous papules on legs
Figure 4:: Scattered erythematous papules on scrotum (red arrows)
Figure 5:: Erosive erythema on the perianal area
Figure 6:: Paronychia-like changes (red arrows)

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship


Conflict of interest

There are no conflicts of interest.


  1. . Amivantamab: First approval. Drugs. 2021;81:1349-53.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , , , , , et al. Antitumor activity of amivantamab (JNJ–61186372), an EGFR–MET bispecific antibody, in diverse models of EGFR exon 20 insertion–driven NSCLC. Cancer Discov. 2020;10:1194-209.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , , , , et al. A novel bispecific antibody targeting EGFR and cMet is effective against EGFR inhibitor-resistant lung tumors. Cancer Res. 2016;76:3942-53.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , , . EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins. Cancer Treat Rev. 2020;90:102105.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , , , , , et al. Amivantamab in EGFR exon 20 insertion–mutated non–small–cell lung cancer progressing on platinum chemotherapy: Initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39:3391-402.
    [CrossRef] [PubMed] [Google Scholar]
  6. , , , , , , et al. Meta-analysis of the effect of Kangfuxin liquid on diabetic patients with skin ulcers. Evid Based Complement Alternat Med. 2021;2021:1334255.
    [CrossRef] [PubMed] [Google Scholar]
Show Sections